Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

Derek Alderson, David Cunningham*, Matthew Nankivell, Jane M. Blazeby, S. Michael Griffin, Adrian Crellin, Heike I. Grabsch, Rupert Langer, Susan Pritchard, Alicia Okines, Richard Krysztopik, Fareeda Coxon, Joyce Thompson, Stephen Falk, Clare Robb, Sally Stenning, Ruth E. Langley

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1249-1260
Number of pages12
JournalLancet oncology
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 2017

Keywords

  • SQUAMOUS-CELL CARCINOMA
  • QUALITY-OF-LIFE
  • RESECTABLE GASTROESOPHAGEAL ADENOCARCINOMA
  • III TRIAL
  • PERIOPERATIVE CHEMOTHERAPY
  • PREOPERATIVE CHEMORADIOTHERAPY
  • JUNCTIONAL CANCER
  • TUMOR-REGRESSION
  • CLINICAL-TRIAL
  • SURGERY

Cite this

Alderson, D., Cunningham, D., Nankivell, M., Blazeby, J. M., Griffin, S. M., Crellin, A., Grabsch, H. I., Langer, R., Pritchard, S., Okines, A., Krysztopik, R., Coxon, F., Thompson, J., Falk, S., Robb, C., Stenning, S., & Langley, R. E. (2017). Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet oncology, 18(9), 1249-1260. https://doi.org/10.1016/S1470-2045(17)30447-3